Growth forecast of drug sales in 2020: drug K reaches the top and drug o "falls out of favor"

Compile newborn EP vantage, a unit of evaluate, recently released its annual analysis report, listing the drugs with the most expected increase and decrease in sales in 2020 according to the consensus forecast of the seller In the top 5 growth, keytruda from MSD is no doubt at the top of the list Its sales in 2020 are expected to increase by $2.6 billion compared with 2018, reaching $14.4 billion Next came Geely's three in one HIV drug, biktarvy, which is expected to increase sales by $2.2 billion in 2020 compared with 2018, to $6.3 billion However, the sharp increase in biktarvy's sales forecast is also accompanied by a decline in the company's sales forecast for the four in one HIV drug genvoya In the third place, ozempic, a long-acting GLP-1 antidiabetic drug of Novo Nordisk, is expected to sell 2.8 billion US dollars in 2020, an increase of 1.1 billion US dollars compared with 2018 The significant increase in the seller's expectation for the sale of the drug is mainly based on the label expansion to reduce the risk of cardiovascular events, and the indication has recently been approved by FDA In fourth place is Sumitomo's atypical antipsychotic drug latuda, which is expected to sell for $1.8 billion in 2020, an increase of $1 billion over 2018 At present, latuda has been listed in many countries to treat schizophrenia and bipolar I depression In September 2019, latuda was launched in China for the treatment of adults with schizophrenia In the fifth place is rituxan of Roche, whose sales are expected to reach US $5.3 billion in 2020, an increase of US $1 billion over 2018 This is mainly due to the settlement agreement between the company and Pfizer on key patents of rituxan Rituxan biosimilars competition was originally expected in 2018, but was postponed to the second half of 2019 In November 2019, TIWA and celltrion launched truxima, the first rituxan bio generic, in the US market Lilly bringer Ingelheim's SGLT2 antidiabetic drug, jardiance, is expected to increase sales by $768 million in 2020 compared with 2018, ranking 9th in the growth list Pfizer's amyloid cardiomyopathy drug vyndaqel is not among the top 5 growth groups, with sales expected to increase by $980 million in 2020 compared with 2018 In terms of reduction, Bristol Myers Squibb's opdivo ranked first The drug is expected to sell $7.9 billion in 2020, a decrease of $0.8 billion compared with 2018 This is mainly due to the huge suppression brought by the repeated success of keytruda, a similar competitive product In the second place is Johnson & Johnson / Bayer anticoagulant xarelto, which is the most widely used non vitamin K antagonist oral anticoagulant in the world, and has been approved for 9 indications Sales of the drug in 2020 are expected to be $6.7 billion, down $0.7 billion from 2018, mainly due to the failure of a key expansion study in 2018 In the third place is neulasta, Amgen's "white medicine", which is expected to sell US $2.6 billion in 2020, a decrease of US $0.7 billion compared with that in 2018 This is mainly due to the bio generic competition in markets outside the United States since 2018, when neulasta's sales have declined significantly In terms of us regulation, three neulasta bio generic drugs have been approved The fourth and fifth are all HIV drugs, which are genvoya of Gilead and triumeq of GlaxoSmithKline The sales in 2020 are expected to be 3.6 billion US dollars and 3 billion US dollars respectively, down 600 million US dollars and 500 million US dollars respectively compared with 2018 In addition to the competition from Gilead, GlaxoSmithKline's increasing dependence on the once-a-month long-acting two drug therapy cabotegravir / rilpivirine (CAB / RPV) in the future is also the reason for the decline of the expectation of trimeqs.